Pharmaceutical The US Food and Drug Administration (FDA) has granted accelerated approval to Hernexeos (zongertinib), from German family owned Boehringer Ingelheim, a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. 27 February 2026